...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of neurology >Progressive multifocal leukoencephalopathy in Finland: a cross-sectional registry study
【24h】

Progressive multifocal leukoencephalopathy in Finland: a cross-sectional registry study

机译：芬兰进行渐进式多焦点白血病：横断面注册表研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

ObjectiveTo investigate if progressive multifocal leucoencephalopathy (PML) incidence has increased in Finland like in the neighbouring Sweden.MethodsNational administrative registries were searched for all PML admissions aged 16years or more in 2004-2014 on all neurological and internal medicine wards in Finland. The mortality data of the patients was extracted from the national causes of death registry. National level data on annual predisposing drug use was obtained from the national pharmaceutical authority.ResultsWe identified 35 PML cases (57% male) with a peak in 2010-2011 that amounted to 49% of all cases. The annual incidence for the entire study period was 0.072/100,000 person-years (95% CI 0.050-0.10) with no temporal trend (p=0.18). Mean age was 57years (22-88years) with no sex difference (p=0.42). Neoplasms (60%), HIV infection (17%) and systemic connective tissue disorders (CTD, 14%) were the most common predisposing conditions. MS was recorded in three cases (9%). The national level use of drugs that predispose to PML increased during the study period, with the exceptions of alemtuzumab and fludarabine. Overall survival was 85% at 90 days, 79% at 1year, and 66% at 5years. Survival was worst in patients with malignancy and best in patients with CTD.ConclusionsPML most often occurs in patients with malignancies and patients with HIV or CTD cover a third. PML incidence in Finland is lower than in Sweden and shows no temporal trend despite increasing use of predisposing drugs. Mortality after PML varies according to the predisposing condition.
机译：ObjectiveTo调查芬兰在邻近瑞典的芬兰进步多焦点的养分（PML）发病率..在芬兰的所有神经系统和内科病房中，在2004 - 2014年的所有PML招生或更多的PML招生中搜查了一项芬兰的所有PML入学。患者的死亡率数据是从国家死亡登记处提取的。从国家制药权，获得了关于年度预测药物使用的国家一级数据。培养史温鉴定了35例PML病例（57％的男性），2010年 - 2011年的峰值达到所有案件的49％。整个研究期的年发病率为0.072 / 100,000人 - 年（95％CI 0.050-0.10），没有时间趋势（P = 0.18）。平均年龄为57岁（22-88年），没有性别差异（p = 0.42）。肿瘤（60％），HIV感染（17％）和全身结缔组织疾病（CTD，14％）是最常见的易感性条件。 MS被记录在三种情况下（9％）。在研究期间，国家一级使用易患PML的药物，具有Alemtuzumab和Fludarabine的例外。整体存活率在90天内为85％，1年的79％，5年的5岁为66％。恶性肿瘤患者的生存率最差，并且最佳CTD.ConclusionsPML，患有恶性肿瘤患者和艾滋病毒或CTD患者的患者。芬兰的PML发病率低于瑞典，尽管越来越多地利用易用药物，但仍没有表现出时间趋势。 PML后的死亡率根据易感性条件而变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号